ImmunoQS

Immunochemical Diagnostic and Therapeutic Strategies based on the Quorum Sensing System - ImmunoQS


The final goal of the ImmunoQS project is to advance the knowledge of the mechanisms involved in the pathogenesis caused by two important microorganisms (Pseudomonas aeruginosa and Staphylococcus aureus) with the clear intention of improving the treatment and diagnosis of infectious diseases caused by these pathogens, through immunochemical studies of their Quorum Sensing (QS) systems as therapeutic and biomarker targets.

Worldwide, infectious diseases are the leading cause of death among children and adolescents and one of the leading causes in adults. There is an increase in antibiotic resistance and fewer new antibiotics are being developed.

The ImmunoQS project proposes developing specific antiboides against relevant QS signalling molecules which regulate secretion of the most important virulence factors and the formation of biofilms. Quenching these QS signals by antibody capture will be investigated as an alternnative therapeutic approach for neutralising both the QS activity and the toxic effect and virulence mechanisms. By suppressing virulence factor expression rather than targeting the bacteria directly, the possibility for developing drug resistance mechanisms may be reduced.

Also, the potential value of the QS molecules as biomarkers of infection will be investigated by developing immunochemical methods addressed at profiling the expression of different QS signalling molecules.

The results obtained from this project may have an extraordinary imact on the biomedical field by increasing the efficiency and reliability of the clinical laboratories and improve the health situation of all citizens by providing them with more personalised and specific treatments. Moreover, important economic benefits may be derived from implementing these technologies in the clinical settings and transferring the technology developed to the private sector.
Partners
Combinatorial Chemistry Unit - Parc Cientific Barcelona
Microbiology Laboratory - Hospital Germans Trias i Pujol
Aseptika Ltd.

Participating Investigators
Prof. Mª-Pilar Marco
Dr. Lluïsa Vilaplana
Funding
Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, Convocatoria 2015, Modalidad 1: en el Marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-3016.
SAF2015-67476-R
©   NANOBIOTECHNOLOGY for DIAGNOSTICS 
www.nb4diagnostics.org - nb4d@iqac.csic.es
Sitemap - Legal Advice Design by: